{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:33:24Z","timestamp":1781660004096,"version":"3.54.5"},"reference-count":30,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"3","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: To investigate the immunophenotypic characteristics and prognostic value of peripheral blood circulating plasma cells (CPCs) in patients with newly diagnosed multiple myeloma (NDMM). Methods: This retrospective study was conducted on NDMM patients treated at Beijing Chaoyang Hospital, Capital Medical University, between January 2020 and June 2023. A total of 57 patients were included, with a median age of 64 years, comprising 27 males. Forty-four patients were assigned to the higher CPCs group and 13 to the lower CPCs group. To compare the proportion of bone marrow plasma cells (BMPCs) between the two groups and to analyse the differences in the immunophenotypes of BMPCs and CPCs. Subsequently, the prognosis of the patients was analysed by COX. Results: The percentage of BMPCs was significantly higher in the higher CPCs group compared to the lower CPCs group (53.07% vs. 15.23%, P&lt;0.001). In the higher CPCs group, BMPCs exhibited decreased expression of CD56 and CD27 but increased expression of CD81 (all P&lt;0.05). The median PFS in the lower CPCs group (17.6 months, 9.12-31.54) was significantly higher than that in the higher CPCs group (14.1 months, 5.08-26.12) (P=0.015). Multivariate Cox regression analysis identified CPCs \u2265 0.0101% (HR=6.721, 95% CI: 3.891-11.224, P&lt;0.001) as the independent prognostic factors for PFS. Conclusions: This study demonstrates distinct immunophenotypic differences between the higher and lower CPCs groups in NDMM patients.<\/jats:p>","DOI":"10.5937\/jomb0-55319","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T10:47:30Z","timestamp":1741258050000},"page":"668-677","source":"Crossref","is-referenced-by-count":1,"title":["Immunophenotypic characteristics and prognostic value of peripheral blood circulating plasma cells in patients with newly diagnosed multiple myeloma"],"prefix":"10.5937","volume":"44","author":[{"given":"Hong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Rajkumar SV . Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 2024; 99(9): 1802-24;","DOI":"10.1002\/ajh.27422"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Firth J. Haematology: multiple myeloma. Clin Med (Lond) 2019; 19(1): 58-60;","DOI":"10.7861\/clinmedicine.19-1-58"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet 2021; 397(10272): 410-27;","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kawano Y, Moschetta M, Manier S, Glavey S, G\u00f6rg\u00fcn GT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev 2015; 263(1): 160-72;","DOI":"10.1111\/imr.12233"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood 2012; 120(1): 20-30;","DOI":"10.1182\/blood-2012-01-379024"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Dogan A, Demircioglu S. Diagnostic importance of bone marrow aspiration evaluation: A single-center study. Pak J Med Sci 2022; 38(4Part-II): 811-5;","DOI":"10.12669\/pjms.38.4.4797"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Rasche L, Chavan SS, Stephens OW , Patel PH, T ytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 2017; 8(1): 268;","DOI":"10.1038\/s41467-017-00296-y"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15(12): e538-48;","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Rath A, Panda T , Dass J, Seth T , Mahapatra M, Tyagi S. Immunophenotypic Profile of Multiple Myeloma: A Tertiary Care Centre Experience. J Lab Physicians 2023; 15(3): 392-8;","DOI":"10.1055\/s-0043-1761204"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P , Paiva B, San-Miguel JF . Roadmap to cure multiple myeloma. Cancer Treat Rev 2021; 100: 102284;","DOI":"10.1016\/j.ctrv.2021.102284"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"van de Donk N. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells. J Clin Oncol 2023; 41(7): 1342-9;","DOI":"10.1200\/JCO.22.02114"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Li Q, Ai L, Zuo L, Li J, Zhao F , Xu A, et al. Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis. Ann Med 2024; 56(1): 2338604;","DOI":"10.1080\/07853890.2024.2338604"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Morice WG, Hanson CA, Kumar S, Frederick LA, Lesnick CE, Greipp PR. Novel multiparameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia 2007; 21(9): 2043-6;","DOI":"10.1038\/sj.leu.2404712"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106(7): 2276-9;","DOI":"10.1182\/blood-2005-05-1858"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gonsalves WI, Rajkumar SV , Gupta V , Morice WG, Timm MM, Singh PP , et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia 2014; 28(10): 2060-5;","DOI":"10.1038\/leu.2014.98"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Muccio VE, Gilestro M, Saraci E, Capra A, Costa A, Ruggeri M, et al. Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics. Blood 2019; 134: 4357;","DOI":"10.1182\/blood-2019-122657"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Abe Y, Narita K, Kobayashi H, Kitadate A, Miura D, Takeuchi M, et al. Pretreatment (18)F-FDG PET\/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging 2019; 46(6): 1325-33;","DOI":"10.1007\/s00259-019-4275-5"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Bae MH, Park SH, Park C-J, Kim BH, Cho Y-U, Jang S, et al. Increased Circulating Plasma Cells Predicts Poor Overall Survival in Symptomatic Plasma Cell Myeloma Patients. Blood 2015; 126(23): 4205;","DOI":"10.1182\/blood.V126.23.4205.4205"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Bertamini L, Grasso M, D'Agostino M, Pascarella A, T osi P , Monaco F , et al. Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity. Blood 2020; 136 (Supplement 1): 12-3;","DOI":"10.1182\/blood-2020-137075"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Cheng Q, Cai L, Zhang Y, Chen L, Hu Y, Sun C. Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models. Front Oncol 2021; 11: 639528;","DOI":"10.3389\/fonc.2021.639528"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Xia Y, Shen N, Zhang R, Wu Y, Shi Q, Li J, et al. High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics. Front Oncol 2023; 13: 1083053;","DOI":"10.3389\/fonc.2023.1083053"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Y ao W , Y ang H, Y ou H, Shang J, Zhai Y , Y an Z, et al. The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients. Front Oncol 2023; 13: 1266868;","DOI":"10.3389\/fonc.2023.1266868"},{"key":"ref23","unstructured":"The guidelines for the diagnosis and management of multiple myeloma in China (2020 revision). Zhonghua nei ke za zhi 2020; 59(5): 341-6;"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Vela-Ojeda J, Esparza MAG, Majluf-Cruz A, Garc\u00eda-Chavez J, Montiel-Cervantes LA, Reyes-Maldonado E, et al. Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens. Int J Hematol 2019; 110(3): 306-12;","DOI":"10.1007\/s12185-019-02679-x"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Sanoja-Flores L, Flores-Montero J, Garc\u00e9s JJ, Paiva B, Puig N, Garc\u00eda-Mateo A, et al. Next generation flow for minimally-invasive blood characterisation of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 2018; 8(12): 117;","DOI":"10.1038\/s41408-018-0153-9"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Paiva B, Paino T , Sayagues JM, Garayoa M, San-Segundo L, Mart\u00edn M, et al. Detailed characterisation of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood 2013; 122(22): 3591-8;","DOI":"10.1182\/blood-2013-06-510453"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun 2018; 9(1): 1691;","DOI":"10.1038\/s41467-018-04001-5"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, et al. Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. Bone Marrow Transplant 2017; 52(8): 1194-8;","DOI":"10.1038\/bmt.2017.91"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Gonsalves WI, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am J Hematol 2020; 95(3): 310-5;","DOI":"10.1002\/ajh.25709"},{"key":"ref30","unstructured":"Chinese expert consensus on the application of flow cytometry for the detectin of circulating plasma cells in plasma cell disorders (2024). Zhonghua Xue Y e Xue Za Zhi 2024; 45(4): 313-21;"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Imunofenotipske karakteristike i prognosti\u010dka vrednost cirkuli\u0161u\u0107ih plazma \u0107elija u perifernoj krvi kod pacijenata sa novodijagnostikovanom multiplim mijelomom"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582503668C.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T16:47:30Z","timestamp":1749833250000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582503668C"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-55319","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}